

## PRESS RELEASE



NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA OR IN AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS, OR SALES OF THE SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.

THIS PRESS RELEASE IS RELEASED FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES AND THE OFFER OF BONDS (AS DEFINED BELOW) DOES NOT CONSTITUTE A PUBLIC OFFER (OTHER THAN TO QUALIFIED INVESTORS) IN ANY JURISDICTION, INCLUDING FRANCE.

THE BONDS MAY ONLY BE OFFERED OR SOLD TO QUALIFIED INVESTORS, WHO COMPRISE, FOR THE PURPOSES OF THIS PRESS RELEASE, PROFESSIONAL CLIENTS AND ELIGIBLE COUNTERPARTIES. THE SECURITIES WILL NOT BE OFFERED OR SOLD TO RETAIL INVESTORS. NO KEY INFORMATION DOCUMENT HAS BEEN OR WILL BE PREPARED PURSUANT TO EU PRIIPS OR UK PRIIPS REGULATION.

### **Korian announces the early redemption of undated bonds convertible into new shares and/or exchangeable for existing shares (ODIRNANE) issued in July 2017 and September 2018 (ISIN: FR0013266087) (the "2017 ODIRNANE")**

Paris, 8 September 2021 - Korian (the "**Company**") announces to the holders of 2017 ODIRNANE (which term includes, for the avoidance of doubt, the further 2017 ODIRNANES issued in September 2018) that following the repurchase offer dated September 1<sup>st</sup>, 2021 to repurchase the 2017 ODIRNANE, the total number of outstanding 2017 ODIRNANE is, as of the date of this notice, less than 10% of the number of 2017 ODIRNANE originally issued.

Consequently, the Company informs the holders of the outstanding 2017 ODIRNANE that it will proceed with the early redemption of such outstanding 2017 ODIRNANE in accordance with Condition 9.3 of the terms and conditions of the 2017 ODIRNANE (the "**Terms and Conditions**", or the "**Conditions**") for the purposes of their cancellation in accordance with applicable law.

The date of early redemption of the 2017 ODIRNANE shall be October 25<sup>th</sup>, 2021 (the "**Early Redemption Date**"). The early redemption price per each 2017 ODIRNANE will amount to EUR 40.21 (being the par value of each 2017 ODIRNANE), together with interest accrued from (and including) July 1<sup>st</sup>, 2021 (being the most recent Interest Payment Date) to (but excluding) the Early Redemption Date, i.e. a total amount of EUR 40.52832 per each 2017 ODIRNANE (the "**Early Redemption Price**").

Pursuant to the Terms and Conditions, the holders of each 2017 ODIRNANE may exercise the Conversion Right in respect thereof to (and including) September 28<sup>th</sup>, 2021 (the "**Last Day of the Exercise Period**").

For the avoidance of doubt, pursuant to the Terms and Conditions:

- (i) the Date of the Request in respect of any such exercise of the Conversion Right shall be required to fall on or prior to the Last Day of the Exercise Period, failing which any such exercise will not be valid and the relevant 2017 ODIRNANES will be redeemed as provided in paragraph (ii) below; and
- (ii) each 2017 ODIRNANE in respect of which the Conversion Right has not been validly exercised such that the Date of the Request falls on or prior to the Last Day of the Exercise Period will be redeemed at the Early Redemption Price on the Early Redemption Date.

## PRESS RELEASE



NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA OR IN AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS, OR SALES OF THE SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.

THIS PRESS RELEASE IS RELEASED FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES AND THE OFFER OF BONDS (AS DEFINED BELOW) DOES NOT CONSTITUTE A PUBLIC OFFER (OTHER THAN TO QUALIFIED INVESTORS) IN ANY JURISDICTION, INCLUDING FRANCE.

THE BONDS MAY ONLY BE OFFERED OR SOLD TO QUALIFIED INVESTORS, WHO COMPRISE, FOR THE PURPOSES OF THIS PRESS RELEASE, PROFESSIONAL CLIENTS AND ELIGIBLE COUNTERPARTIES. THE SECURITIES WILL NOT BE OFFERED OR SOLD TO RETAIL INVESTORS. NO KEY INFORMATION DOCUMENT HAS BEEN OR WILL BE PREPARED PURSUANT TO EU PRIIPS OR UK PRIIPS REGULATION.

Holders of the 2017 ODIRNANE are reminded that in order to exercise their Conversion Right, a request to that effect must be made to the financial intermediary holding their 2017 ODIRNANE in a securities account. Any request for exercise shall be irrevocable as of its receipt by the relevant financial intermediary.

The date of request for exercise shall be the Business Day during which the last of the following conditions (1) and (2) below is met, at 4:00 pm Paris time at the latest, or the following Business Day if any such condition is met after 4:00 pm Paris time (the "**Date of the Request**"):

(1) CACEIS Corporate Trust in its capacity as centralising agent (the "**Centralising Agent**") will have received the request for exercise from the financial intermediary in the books of which the 2017 ODIRNANE are held in securities account;

(2) the relevant 2017 ODIRNANE will have been transferred to the Centralising Agent by the relevant financial intermediary.

Any request for exercise of the Conversion Right sent to the Centralising Agent will be effective as of the first Trading Day following the Date of the Request (such date being the "**Exercise Date**").

Pursuant and subject to the Terms and Conditions, the holders of the 2017 ODIRNANE in respect of which the Conversion Right has been validly exercised will receive, at the option of the Company, either:

- an amount in cash or a combination of cash and new and/or existing shares of the Company no later than the fourth Trading Day following the end of the relevant Calculation Period; or
- only new and/or existing shares of the Company no later than the fourth Trading Day following the end of the Notification Period.

Capitalised terms used in this notice and not otherwise defined herein shall have the meanings given to them in the Terms and Conditions.

For more information, holders of 2017 ODIRNANE are invited to consult the Terms and Conditions.

## PRESS RELEASE



NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA OR IN AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS, OR SALES OF THE SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.

THIS PRESS RELEASE IS RELEASED FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES AND THE OFFER OF BONDS (AS DEFINED BELOW) DOES NOT CONSTITUTE A PUBLIC OFFER (OTHER THAN TO QUALIFIED INVESTORS) IN ANY JURISDICTION, INCLUDING FRANCE.

THE BONDS MAY ONLY BE OFFERED OR SOLD TO QUALIFIED INVESTORS, WHO COMPRISE, FOR THE PURPOSES OF THIS PRESS RELEASE, PROFESSIONAL CLIENTS AND ELIGIBLE COUNTERPARTIES. THE SECURITIES WILL NOT BE OFFERED OR SOLD TO RETAIL INVESTORS. NO KEY INFORMATION DOCUMENT HAS BEEN OR WILL BE PREPARED PURSUANT TO EU PRIIPS OR UK PRIIPS REGULATION.

### About Korian

Korian, the leading European care services group for elderly and fragile people. [www.korian.com](http://www.korian.com)

**Korian has been listed on Euronext Paris Section A since November 2006 and is included in the following indices: SBF 120, CAC Health Care, CAC Mid 60, CAC Mid & Small and MSCI Global Small Cap**

**Euronext ticker: KORI - ISIN: FR0010386334 – Reuters: KORI.PA – Bloomberg: KORI.FP**

### INVESTOR RELATIONS

#### **Sarah Mingham**

VP Investor Relations  
& Financing

[sarah.mingham@korian.com](mailto:sarah.mingham@korian.com)

Tel: +33 (0)1 55 37 53 55

#### **Carole Alexandre**

Deputy Head of  
Investor Relations

[carole.alexandre@korian.com](mailto:carole.alexandre@korian.com)

Tel: +33 (0)7 64 65 22 44

### MEDIA CONTACTS

#### **Jean-Marc Plantade**

Head of Press Relations

[jean-marc.plantade@korian.fr](mailto:jean-marc.plantade@korian.fr)

Tel: +33 (0)7 62 90 32 58

#### **Cyrille Lachèvre**

Deputy Head of Press Relations

[cyrille.lachevre@korian.fr](mailto:cyrille.lachevre@korian.fr)

Tel: +33 (0)7 61 53 54 86

#### **Marjorie Castoriadis**

Head of Media Relations

[marjorie.castoriadis@korian.fr](mailto:marjorie.castoriadis@korian.fr)

Tel: +33 (0)7 63 59 88 81

### IMPORTANT NOTICE

*This press release may not be released, published or distributed, directly or indirectly, in or into the United States of America, Australia, Canada or Japan. The distribution of this press release may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes, should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.*

*No communication or information relating to the issuance by Korian of the 2017 ODIRNANE may be transmitted to the public in a country where there is a registration obligation or where an approval is required. No action has been or will be taken in any country in which such registration or approval would be required. The issuance by the Company or the subscription of the 2017 ODIRNANE may be subject to legal and regulatory restrictions in certain jurisdictions; Korian do not assume any liability in connection with the breach by any person of such restrictions.*